PL3655013T3 - Ukierunkowanie na synaptogirynę-3 w leczeniu tauopatii - Google Patents
Ukierunkowanie na synaptogirynę-3 w leczeniu tauopatiiInfo
- Publication number
- PL3655013T3 PL3655013T3 PL18740228.4T PL18740228T PL3655013T3 PL 3655013 T3 PL3655013 T3 PL 3655013T3 PL 18740228 T PL18740228 T PL 18740228T PL 3655013 T3 PL3655013 T3 PL 3655013T3
- Authority
- PL
- Poland
- Prior art keywords
- synaptogyrin
- tauopathy
- targeting
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5058—Neurological cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/544—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Plant Pathology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17181659 | 2017-07-17 | ||
| PCT/EP2018/069228 WO2019016123A1 (en) | 2017-07-17 | 2018-07-16 | TARGETING SYNAPTOGYRIN-3 IN THE TREATMENT OF TAUOPATHY |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3655013T3 true PL3655013T3 (pl) | 2022-08-22 |
Family
ID=59387892
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18740228.4T PL3655013T3 (pl) | 2017-07-17 | 2018-07-16 | Ukierunkowanie na synaptogirynę-3 w leczeniu tauopatii |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11332526B2 (pl) |
| EP (2) | EP4036234A1 (pl) |
| CA (1) | CA3069998A1 (pl) |
| DK (1) | DK3655013T3 (pl) |
| ES (1) | ES2923015T3 (pl) |
| PL (1) | PL3655013T3 (pl) |
| WO (1) | WO2019016123A1 (pl) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113817728A (zh) * | 2020-06-19 | 2021-12-21 | 四川大学华西医院 | 一种有效干扰Tau蛋白表达的重组慢病毒及其应用 |
| WO2022212208A1 (en) * | 2021-03-29 | 2022-10-06 | University Of Massachusetts | Oligonucleotides for syngr-3 modulation |
| CA3229305A1 (en) | 2021-08-16 | 2023-02-23 | Vib Vzw | Oligonucleotides for modulating synaptogyrin-3 expression |
| WO2024160756A1 (en) * | 2023-01-30 | 2024-08-08 | Vib Vzw | Suppressors of tauopathies |
| EP4669749A1 (en) | 2023-02-21 | 2025-12-31 | Vib Vzw | OLIGONUCLEOTIDES TO MODULATE SYNAPTOGYRIN-3 EXPRESSION |
| WO2024175586A2 (en) * | 2023-02-21 | 2024-08-29 | Vib Vzw | Inhibitors of synaptogyrin-3 expression |
| WO2025089345A1 (ja) * | 2023-10-25 | 2025-05-01 | 株式会社Jiksak Bioengineering | 抗シナプトジャイリン3抗体 |
| WO2026041784A1 (en) | 2024-08-23 | 2026-02-26 | Vib Vzw | Oligonucleotides for modulating synaptogyrin-3 expression |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1452868A2 (en) | 2003-02-27 | 2004-09-01 | Pepscan Systems B.V. | Method for selecting a candidate drug compound |
| WO2007140975A1 (en) * | 2006-06-06 | 2007-12-13 | F. Hoffmann-La Roche Ag | Synaptic proteins as biomarker for alzheimer’s disease |
| WO2008020435A2 (en) * | 2006-08-15 | 2008-02-21 | Quark Pharmaceuticals, Inc | Compositions and methods for treatment of mood disorders |
| DK2257624T5 (da) | 2008-02-05 | 2012-09-10 | Medical Res Council | Fremgangsmåder og sammensætninger |
| US20100092470A1 (en) | 2008-09-22 | 2010-04-15 | Icb International, Inc. | Antibodies, analogs and uses thereof |
-
2018
- 2018-07-16 CA CA3069998A patent/CA3069998A1/en active Pending
- 2018-07-16 DK DK18740228.4T patent/DK3655013T3/da active
- 2018-07-16 PL PL18740228.4T patent/PL3655013T3/pl unknown
- 2018-07-16 ES ES18740228T patent/ES2923015T3/es active Active
- 2018-07-16 WO PCT/EP2018/069228 patent/WO2019016123A1/en not_active Ceased
- 2018-07-16 EP EP22160146.1A patent/EP4036234A1/en not_active Withdrawn
- 2018-07-16 EP EP18740228.4A patent/EP3655013B1/en active Active
- 2018-07-16 US US16/631,400 patent/US11332526B2/en active Active
-
2022
- 2022-04-20 US US17/724,632 patent/US20220403021A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP4036234A1 (en) | 2022-08-03 |
| EP3655013A1 (en) | 2020-05-27 |
| US20200216531A1 (en) | 2020-07-09 |
| CA3069998A1 (en) | 2019-01-24 |
| ES2923015T3 (es) | 2022-09-22 |
| US20220403021A1 (en) | 2022-12-22 |
| US11332526B2 (en) | 2022-05-17 |
| DK3655013T3 (da) | 2022-07-11 |
| EP3655013B1 (en) | 2022-04-13 |
| WO2019016123A1 (en) | 2019-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL271085A (en) | Bacteria for the treatment of disorders | |
| PL3655013T3 (pl) | Ukierunkowanie na synaptogirynę-3 w leczeniu tauopatii | |
| IL257978B (en) | Use of pasteurized akkermansia for treating metabolic disorders | |
| PL3423105T3 (pl) | Koniugaty przeciwciało-lek oparte na erybulinie i sposoby zastosowania | |
| SI3785717T1 (sl) | Postopki za zdravljenje okužb s Coronaviridae | |
| IL263680A (en) | Combination therapies | |
| PL3265053T3 (pl) | Sposoby leczenia skóry | |
| HUE057426T2 (hu) | Heteroaril-szubsztituált béta-hidroxietilamin-származékok magas vécukorszint kezelésére való alkalmazásra | |
| HUE049072T2 (hu) | AXL-specifikus ellenanyag-drog konjugátumok rák kezelésére | |
| HUE061761T2 (hu) | Tetrahidropiranil-amino-pirrolopirimidinon felhasználásra BTK-által közvetített zavarok kezelésében | |
| HUE059662T2 (hu) | Eljárás terápiás immunsejtek hatékonyságának fokozására | |
| EP3063691A4 (en) | DYNAMIC DE-IDENTIFICATION AND ANONYMITY | |
| IL260684B (en) | Treatment for modulating gut microbiota | |
| PL3186244T3 (pl) | Analogi dioksolanowe urydyny w leczeniu raka | |
| HUE056006T2 (hu) | Kombináció Parkinson-kór kezelésére | |
| IL262852A (en) | Treatment of complement-mediated disorders | |
| HUE062055T2 (hu) | GLA domének mint terápiás szerek | |
| IL242971B (en) | Ventricular far field reduction | |
| EP3310376A4 (en) | MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF | |
| IL256206A (en) | Mct4 inhibitors for treating disease | |
| HUE050485T2 (hu) | Tauopathia kezelési módszerei | |
| PL3236960T3 (pl) | Fluralaner do zastosowania w leczeniu demodekozy | |
| SI3188599T1 (sl) | Zdravljenje na osnovi anamorelina | |
| DK3302478T3 (da) | Pac-1 kombinations behandling | |
| HUE056798T2 (hu) | Imatinib stroke kezelésében való alkalmazásra |